BiotechTube

Eplontersen

Phase 3Recruiting
1 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Conditions

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Trial Timeline

Nov 30, 2022 → Aug 1, 2029

NCT ID
NCT05667493

About Eplontersen

Eplontersen is a phase 3 stage product being developed by AstraZeneca for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05667493. Target conditions include Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM).

What happened to similar drugs?

0 of 4 similar drugs in Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) were approved

Approved (0) Terminated (0) Active (4)
🔄Eplontersen + PlaceboAstraZenecaPhase 3
🔄Nucresiran + VutrisiranAlnylam PharmaceuticalsPhase 3
🔄EplontersenIonis PharmaceuticalsPhase 3
🔄Inotersen + EplontersenIonis PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05667493Phase 3Recruiting

Competing Products

9 competing products in Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

See all competitors
ProductCompanyStageHype Score
Eplontersen Solution for InjectionAstraZenecaPhase 1
29
Eplontersen + PlaceboAstraZenecaPhase 3
44
PatisiranAlnylam PharmaceuticalsPre-clinical
23
PatisiranAlnylam PharmaceuticalsPre-clinical
23
ALN-TTRSC02 + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
26
Nucresiran + VutrisiranAlnylam PharmaceuticalsPhase 3
44
ALN-TTRSC04 + PlaceboAlnylam PharmaceuticalsPhase 1
26
EplontersenIonis PharmaceuticalsPhase 3
41
Inotersen + EplontersenIonis PharmaceuticalsPhase 3
37